Company / SG&A Expense
Revvity SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$991.9M
FY2025
5-year range
$975.2M / $1.0B
FY2021-FY2025
Trend
-0.2%
vs FY2024
Sector context
#47 of 158
Health Care
What the data says
At $992M, Revvity's sg&a expense ranks #112 of 158 in the Health Care sector. SG&A Expense has declined for 3 consecutive years, from $1.0B in FY2022 to $992M in FY2025.
Based on SEC 10-K filings.
$992M in FY2025 with a 5-year CAGR of +6.7%.
Improved from $1.0B to $992M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -1.1%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Sector benchmark
#112 of 158 in Health CareTop 70% of 158This company $991.9M Sector average $175.9B
▼
-99.4% below sector average
Key checks
Key Insights
- Revvity's sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of +6.7%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.2% year-over-year.
- Ranks #47 out of 158 companies in the Health Care sector.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $991.9M | -0.2% |
| FY2024 | $994.1M | -2.8% |
| FY2023 | $1.0B | -0.3% |
| FY2022 | $1.0B | +5.2% |
| FY2021 | $975.2M | +36.1% |
| FY2020 | $716.5M | -12.1% |
| FY2019 | $815.3M | +0.4% |
| FY2018 | $811.9M | +29.7% |
| FY2017 | $626.0M | +6.0% |
| FY2016 | $590.5M | +0.6% |
As of FY2025 · SEC 10-K · Updated Mar 14, 2026